Skip to main content

What the FDA labels say about taking them together

Fosamprenavir and nimodipine

Fosamprenavir's FDA label of September 15, 2023 names nimodipine in its drug interactions section; the nimodipine label PlainMeds reads does not name fosamprenavir. The fosamprenavir label: “Use with caution. Clinical monitoring of patients is recommended.”

Check it at the source: the fosamprenavir FDA label on DailyMed (effective September 15, 2023, Mylan Pharmaceuticals Inc.); the nimodipine FDA label on DailyMed (effective August 30, 2024, Azurity Pharmaceuticals, Inc.).

What does the fosamprenavir label say about nimodipine?

Fosamprenavir label, drug interactions

Concomitant Drug Class/Drug Name: Calcium channel blockers: Diltiazem, felodipine, nifedipine, nicardipine, nimodipine, verapamil, amlodipine, nisoldipine, isradipine; Effect on Concentration of Amprenavir or Concomitant Drug: ↑ Calcium channel blockers; Clinical Comment: Use with caution. Clinical monitoring of patients is recommended.

Source: FDA drug label (Fosamprenavir Calcium), Mylan Pharmaceuticals Inc., effective September 15, 2023 (SPL set 3a1424d8-844c-4e24-9ebd-b2c2b61b61a3), via openFDA; the full label on DailyMed

What does the nimodipine label say about fosamprenavir?

Nimodipine's label (effective August 30, 2024) does not name fosamprenavir in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Nymalize), Azurity Pharmaceuticals, Inc., effective August 30, 2024 (SPL set e660fa26-b5c4-4d6d-8887-9e22b6666a10), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

2Fosamprenavir generic labelers
3Nimodipine generic labelers
FosamprenavirNimodipine
Labeled forHIVn/a
Boxed warningNoNo
Pharmacy cost (NADAC)n/a$1.37 per capsule 30 mg capsule
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?